Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation

被引：0
作者：
T Kuittinen
M Husso-Saastamoinen
P Sipola
O Vuolteenaho
M Ala-Kopsala
T Nousiainen
E Jantunen
J Hartikainen
机构：
[1] Kuopio University Hospital,Department of Medicine
[2] Kuopio University Hospital,Department of Radiology
[3] University of Oulu,Department of Physiology
[4] Biocenter Oulu,undefined
来源：
Bone Marrow Transplantation | 2005年 / 36卷
关键词：
high-dose therapy; cardiotoxicity; natriuretic peptides; magnetic resonance imaging; cyclophosphamide; non-Hodgkin's lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY. We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m2/day as a part of BEAC high-dose therapy (HDT). Magnetic resonance imaging (MRI) and plasma natriuretic peptide (NT-proBNP, NT-proANP) measurements were performed prior to HDT (d-7) and just after completing HDT (d-2). After the high-dose CY left atrial end-systolic area increased from 15.2±1.2 to 18.5±1.4 cm2 (P=0.001), left ventricular end-diastolic volume from 136.1±12.3 to 156.6±11.1 cm3 (P=0.04) and left ventricular end-systolic volume from 67.4±7.8 to 75.3±7.1 cm3 (P=0.018). However, no significant change in left ventricular ejection fraction (LVEF) was observed. At the same time, plasma levels of NT-proBNP increased from 134.9±53.3 to 547.1±168.4 pmol/l (P=0.003) and NT-proANP from 481.1±105.5 to 1056.6±193.1 pmol/l (P=0.001), respectively. To conclude, high-dose CY results in very acute cardiac toxicity characterised by enlargement of the heart chambers in NHL patients previously treated with anthracyclines. This toxicity can be detected with increased concentrations of circulating natriuretic peptides but not with LVEF measurement.
引用
收藏
页码：1077 / 1082
页数：5
相关论文
共 63 条
[1]  
Gratwohl A(2004)Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indications and impact of team density. A report of the EBMT activity survey Bone Marrow Transplant 34 855-875
[2]  
Schmid O(1986)Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations Cancer 57 2061-2069
[3]  
Baldomero H(1981)Cardiotoxicity associated with high-dose cyclophosphamide therapy Arch Intern Med 141 758-763
[4]  
Cazin B(1990)Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings Bone Marrow Transplant 5 91-98
[5]  
Gorin NC(1976)Acute lethal carditis caused by high-dose combinationchemotherapy Lancet 1 58-62
[6]  
Laporte JP(2001)Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997 Bone Marrow Transplant 28 283-287
[7]  
Gottdiener J(1991)Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens J Clin Oncol 9 1215-1223
[8]  
Appelbaum F(2001)Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m Bone Marrow Transplant 28 277-282
[9]  
Ferrans V(1994)) cyclophosphamide J Clin Oncol 12 998-1004
[10]  
Kupari M(2005)Cardiac toxicity of bone marrow transplantation: predictive value of cardiac evaluation before transplant Bone Marrow Transplant 35 323-334
1234567